Loading
Purinostat is an experimental investigational agent whose form is not stated in the registry from Chengdu Zenitar Biomedical Technology in phase 3 trials for diffuse large B-cell lymphoma and multiple myeloma, with its target not yet stated publicly.
Purinostat is an investigational agent whose form is not stated in the registry developed by Chengdu Zenitar Biomedical Technology. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: The subjects in the experimental group will receive treatment with Purinostat Mesylate for injection. The dosage is 11.2 mg/m2. Each administration cycle consists of intravenous infusion on days 1, 4, 8, and 11. The administration cycle las. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07011056 (A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma), in diffuse large B-cell lymphoma and multiple myeloma. The largest, NCT07011056, plans to enrol 390 participants with primary completion expected 2029-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.Purinostat slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Purinostat" OR ABSTRACT:"Purinostat" OR TITLE:"Purinostat Mesylate" OR ABSTRACT:"Purinostat Mesylate") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Purinostat, not a curated reading list.
Shares Chengdu Zenitar Biomedical Technology, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Multiple myeloma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Multiple myeloma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Diffuse large B-cell lymphoma and the tag pipeline.